E
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019
E

New developments in Multiple Myeloma

We take a look at several key developments in myeloma on the antibody and cell therapy front.

February 11, 2019
E

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019
E

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019
E

A novel approach to cell therapy

Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours

January 4, 2019
E

Potential of CAR T cell therapy in CLL

How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.

December 10, 2018
E

ASH18 Highlights from Day 3

Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!

December 3, 2018
E

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018
E

ASH18 Highlights from Day 1

Highlights from Day 1 of the 2018 ASH conference held in San Diego

December 1, 2018
E

ASH18 Preview 3 – BCMA

From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?

November 26, 2018
E

ASH18 Preview 2 Late Breaking Abstracts

What to watch out for in the ASH18 LBA session

November 20, 2018
E

Creating order from the ASH18 data dump

A top-line review of the ASH18 abstract palooza

November 1, 2018